Trial News & Events

NEALS at the AAN

Members are welcome to join us on Tuesday, May 7th from 07:15am - 08:15am for a NEALS Consortium satellite meeting at the 71st American Academy of Neurology Annual Meeting!

NEALS Launches ALS Genetic Access Program

The NEALS ALS Genetic Access Program (ALS GAP) provides clinical genetics services to pALS who are under the care of a registered NEALS clinician. Funded by the Muscular Dystrophy Association, The ALS Association, and Biogen, and administered by NEALS, this program includes clinical genetic testing and genetic counseling via telemedicine. There is no cost to the patient or clinic.

29th International Symposium on ALS/MND

Over a dozen NEALS members chaired the daily sessions over the three-day event, and 15 members presented platforms during the meeting.  Of the more than 500 posters presented during the event, over 60 were submitted by NEALS members. 

Ezogabine treatment shown to reduce motor neuron excitability in ALS patients

Brian Wainger, MD, PhD, of the Healey Center for ALS at Massachusetts General Hospital (MGH) presented initial, top-level results of a recently completed phase 2 clinical trial of ezogabine (also called retigabine) on December 9 at the Motor Neurone Disease Association annual meeting in Glasgow, Scotland.

NEALS Meeting at the MND Symposium

Please join us for a presentation on plans for an ALS Platform Trial through the NEALS Consortium. The NEALS satellite meeting will be held on Sunday, December 9th from 7:15 – 8:15 AM.

NEALS Satellite Meeting at AAN 2018

There will be a NEALS Consortium satellite meeting at the 70th AAN Annual Meeting on Wednesday, April 25, 2018.